EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

KLF12 as a potential biomarker for lateral pelvic lymph node metastases in advanced rectal cancer

Tianxian Xiao, Fangze Wei, Sicheng Zhou, Fuqiang Zhao, Fei Huang, Liu Qian

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-03991-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Tianxian Xiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, National Cancer Center / National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical S…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Kruppel-Like Transcription Factors, Biomarkers, Tumor, Lymph Nodes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rectal cancer accounts for approximately 40% of colorectal cancer cases, and lateral pelvic lymph node (LPLN) metastasis in rectal cancer significantly increases the local recurrence rate. Despite its clinical significance, studies on the molecular biology of LPLN metastasis are relatively scarce. In this study, we aimed to elucidate the underlying mechanisms by identifying hub regulatory genes in LPLN tissues and analyzing differentially expressed genes shared between tumor and pericarcinomatous tissues within our clinical cohort. To investigate the biological functions of these hub regulatory genes, we performed GSEA, GO, and KEGG pathway analyses on mRNA-Seq data. Among the identified hub genes, KLF12 emerged as a pivotal regulatory gene in rectal cancer. We further explored its clinical relevance and biological function. Our findings, validated using public databases, clinical cohort data, and immunohistochemistry (IHC), identified KLF12 as a specific marker for LPLN. Additionally, KLF12 expression exhibited a strong correlation with disease-free survival (DFS). According to clinical data, significant differences in KLF12 expression exist between groups based on factors such as age, gender, tumor location, pathological N stage, and postoperative tumor residue. Both treatment outcomes (DFS) and receiver operating characteristic curves (AUCs) were significantly associated with KLF12 expression. Furthermore, KLF12 demonstrated a strong association with immune cell infiltration, immune checkpoint expression, and immunophenoscore (IPS), indicating its potential regulatory role in immunotherapy. Functional molecular experiments revealed that KLF12 overexpression inhibited the proliferation, migration, and invasion of SW620 cells. In conclusion, leveraging mRNA-Seq data, TCGA database analysis, immune infiltration data, and biological function assessments, we confirmed that KLF12 could serve as an effective predictive marker and potential therapeutic target for LPLN metastasis. These findings suggest that KLF12 may be instrumental in assessing predictive risk and identifying novel therapeutic targets for patients with rectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsKruppel-Like Transcription FactorsBiomarkers, TumorLymph NodesHumansLymphatic MetastasisMaleFemaleMiddle AgedPrognosisGene Expression Regulation, NeoplasticPelvisAgedCell Line, Tumor

Stichwörter der Autor:innen

KLF12Lateral pelvic lymph nodeMarkerRectal cancerTarget

Substanzen

Kruppel-Like Transcription FactorsBiomarkers, TumorKLF12 protein, human

Autor:innen und Institutionen

  • Department of Colorectal Surgery, National Cancer Center / National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Breast Disease Center, Peking University First Hospital, Beijing, 100034, China.
  • Department of Colorectal Surgery, National Cancer Center / National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. fcwp…

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • National Key Research and Development Program of China

Zitieren

APA

Xiao, T., Wei, F., Zhou, S., Zhao, F., Huang, F., & Qian, L. (2025). KLF12 as a potential biomarker for lateral pelvic lymph node metastases in advanced rectal cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-03991-8

Vancouver

Xiao T, Wei F, Zhou S, Zhao F, Huang F, Qian L. KLF12 as a potential biomarker for lateral pelvic lymph node metastases in advanced rectal cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-03991-8

BibTeX
@article{Xiao2025,
  author = {Xiao, Tianxian and Wei, Fangze and Zhou, Sicheng and Zhao, Fuqiang and Huang, Fei and Qian, Liu},
  title = {KLF12 as a potential biomarker for lateral pelvic lymph node metastases in advanced rectal cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-03991-8}
}
Kostenlos starten →